Status:
COMPLETED
Effect of Preoperative Recombinant Human Erythropoietin on Transfusion Risk in Valvular Heart Surgery
Lead Sponsor:
Yonsei University
Conditions:
Cardiac Surgery
Eligibility:
All Genders
20+ years
Phase:
NA
Brief Summary
The administration of rhEPO on the one day before cardiac surgery will be effective to decrease the bleeding due to the surgery.
Eligibility Criteria
Inclusion
- The 90 patients who are planned to have the heart surgery during this study period.(minimum age 20)
Exclusion
- Uncontrolled hypertension(diastolic blood pressure(DBP)\>100 mmHg), Hct \> 45%, Plt. count)\>450,000
- There are no history of seizure, thrombus, cancer, acute hepatitis, alcoholism, peripheral blood vessel disease, pure red blood cell dysfunction, liver function failure, chronic multiple arthritis.
- No pregnancy, acute hyper parathyroidism.
Key Trial Info
Start Date :
April 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2010
Estimated Enrollment :
74 Patients enrolled
Trial Details
Trial ID
NCT00939978
Start Date
April 1 2009
End Date
July 1 2010
Last Update
October 7 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Severance hospital
Seoul, South Korea, 120-752